Raman Joshi1. 1. Department of Rheumatology, Brampton Campus, William Osler Health Sciences Centre, Brampton, Ontario, Canada.
Abstract
OBJECTIVE: To evaluate the efficacy of intraarticular corticosteroid injections for osteoarthritis (OA) of the first carpometacarpal (CMC) joint. METHODS: This was a prospective case series of patients presenting to a community rheumatology clinic with OA of the 1st CMC joint. A total of 0.25 ml of methylprednisolone acetate was injected into the 1st CMC joint in 25 patients, who were followed for one year. RESULTS: A significant improvement in the visual analog scale (VAS) for pain was noted at one month but not at 3, 6, or 12 months postinjection. However, 5 patients were pain-free at 12 months postinjection. Many patients noted improvement in tasks such as lifting a full cup and turning a faucet. Injections were well tolerated, with only 2 patients noting minor side effects. CONCLUSION: These results suggest that intraarticular corticosteroid injection for 1st CMC OA is a well tolerated procedure. A significant longterm benefit of corticosteroid injection for 1st CMC OA was not observed.
OBJECTIVE: To evaluate the efficacy of intraarticular corticosteroid injections for osteoarthritis (OA) of the first carpometacarpal (CMC) joint. METHODS: This was a prospective case series of patients presenting to a community rheumatology clinic with OA of the 1st CMC joint. A total of 0.25 ml of methylprednisolone acetate was injected into the 1st CMC joint in 25 patients, who were followed for one year. RESULTS: A significant improvement in the visual analog scale (VAS) for pain was noted at one month but not at 3, 6, or 12 months postinjection. However, 5 patients were pain-free at 12 months postinjection. Many patients noted improvement in tasks such as lifting a full cup and turning a faucet. Injections were well tolerated, with only 2 patients noting minor side effects. CONCLUSION: These results suggest that intraarticular corticosteroid injection for 1st CMC OA is a well tolerated procedure. A significant longterm benefit of corticosteroid injection for 1st CMC OA was not observed.
Authors: Nazim Karalezli; Tunc Cevat Ogun; Senay Kartal; Sacide Nur Saracgil; Mustafa Yel; Ibrahim Tuncay Journal: Clin Rheumatol Date: 2006-06-24 Impact factor: 2.980
Authors: Lisa A Mandl; Robert N Hotchkiss; Ronald S Adler; Stephen Lyman; Aaron Daluiski; Scott W Wolfe; Jeffrey N Katz Journal: Curr Med Res Opin Date: 2009-09 Impact factor: 2.580
Authors: W Zhang; M Doherty; B F Leeb; L Alekseeva; N K Arden; J W Bijlsma; F Dinçer; K Dziedzic; H J Häuselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; E Maheu; E Martín-Mola; K Pavelka; L Punzi; S Reiter; J Sautner; J Smolen; G Verbruggen; I Zimmermann-Górska Journal: Ann Rheum Dis Date: 2006-10-17 Impact factor: 19.103